Interview
with Neil Love, MD Breast Cancer Update for Medical Oncologists,
Program 6 2000
Play
Audio Below:
Some
of the trials were of tamoxifen versus nothing — that is, tamoxifen
versus no systemic therapy. Other trials were tamoxifen plus chemotherapy
versus the same chemotherapy alone. And in both cases, there was
benefit from tamoxifen. So, tamoxifen plus chemotherapy was better
than chemotherapy alone if the woman had ER+ disease. And I think
that this is something where people are saying, "Should I be using
chemotherapy or should I be using tamoxifen?" and that’s really
not the right way to be thinking. If you’re going to go to
the trouble of giving surgery, if you’re going to go to the
trouble of giving chemotherapy, then you must be saying, "This is
serious disease." And in those circumstances, the extra benefit
that you get, if it’s ER+ disease, from giving tamoxifen, really
is quite substantial. It’s about as substantial as the effects
of the chemotherapy. So, I think it has been a mistake to be thinking
of chemo or tamoxifen. If the woman’s got ER+ disease, if it’s
worth giving chemo, then it’s going to be worth giving tamoxifen,
as well.
Relevant
Articles:
Selective
estrogen receptor modulators: Structure, function, and clinical
use [Review]. Osborne,
C. K. and Fuqua, S. A. W. Journal of Clinical Oncology. 18(17):3172-3186,
2000 Sep.
Similarities
and distinctions in the mode of action of different classes of antioestrogens
[Review]. Wakeling,
A. E. Endocrine-Related Cancer. 7(1):17-28, 2000 Mar. No abstract
Approaches
targeted to estrogen receptors for treatment of tamoxifen-resistant
breast cancer: A brief overview. Terakawa, N. (Reprint available from: Terakawa N Tottori Univ,
Sch Med, Dept Obstet & Gynecol Yonago Tottori 683 Japan)..
Oncology. 59(Suppl 1):3-4, 2000. No abstract
Preliminary
assessment of cognitive function in breast cancer patients treated
with tamoxifen. Paganini-Hill,
A. and Clark, L. J. Breast Cancer Res.earch & Treatment. 64(2):165-176,
2000 Nov.
Symposium
overview: Estrogens and antiestrogens in managing the patient with
breast cancer. Newman,
L. A.; Wood, W. C.; Sellin, R. V.; Morrow, M.; Vogel, C., and Singletary,
S. E. (Reprint available from: Singletary SE Univ Texas, MD Anderson
Canc Ctr, Dept Surg Oncol 1515 Holcombe Blvd,Box 106 Houston, TX
77030 USA).. Annals of Surgical Oncology. 7(8):568-574, 2000 Sep.
In process
The
ovary: cysts, screening, and tamoxifen. Mourits,
M. J. E.; van der Zee, A. G. J.; Willemse, P. H. B., and de Vries,
E. G. E. (Reprint available from: de Vries EGE Univ Groningen Hosp,
Dept Med Oncol POB 30 001 NL-9700 RB Groningen Netherlands). Lancet.
355(9220):2078-2079, 2000 Jun 10.
Concentrations
of tamoxifen and its major metabolites in hormone
responsive and resistant breast tumours. MacCallum, J.; Cummings, J.; Dixon, J. M., and Miller, W. R.
(Reprint available from: MacCallum J Napier Univ, Dept Life Sci
Merchiston Campus,Colinton Rd Edinburgh EH10 5DT Midlothian Scotland)..
British Journal of Cancer. 82(10):1629-1635, 2000 May.
How
is tamoxifen's action subverted? Jordan, V. C. (Reprint available from: Jordan VC Northwestern
Univ, Sch Med, Rober H Lurie Comprehens Canc Ctr 303 E Chicago Ave,Olson
Pavil 8258 Chicago, IL 60611 USA). Journal of the National Cancer
Institute. 92(2):92-94, 2000 Jan 19. No abstract
Serum
lipid levels during and after adjuvant toremifene or tamoxifen therapy
for breast cancer. Joensuu, H.; Holli, K.; Oksanen, H., and Valavaara, R. (Reprint
available from: Joensuu H Univ Helsinki, Cent Hosp, Dept Oncol Haartmaninkatu
4,POB 180 FIN-00029 Helsinki Finland). Breast Cancer Research &
Treatment. 63(3):225-234, 2000 Oct. In process
One
step forward or one step back with tamoxifen? Gelmon, K. (Reprint available from: Gelmon K British Columbia
Canc Agcy Vancouver BC V5Z 4E6 Canada). Lancet. 356(9233):868-869,
2000 Sep 9. No abstract
Endometrial
protection from tamoxifen-stimulated changes by a evonorgestrel-releasing
intrauterine system: a randomised controlled trial. Gardner, F. J. E.; Konje, J. C.; Abrams, K. R.; Brown, L. J.
R.; Khanna, S.; Al-Azzawi, F.; Bell, S. C., and Taylor, D. J.. Lancet.
356(9243):1711-1717, 2000 Nov 18. No abstract
Combined
endocrine therapy for breast cancer - New life for an old idea? Davidson, N. E. (Reprint available from: Davidson NE Johns Hopkins
Oncol Ctr 1650 Orleans St, Rm 409 Baltimore, MD 21231 USA). Journal
of the National Cancer Institute. 92(11):859-860, 2000 Jun 7. No
abstract
Risk
and prognosis of endometrial cancer after tamoxifen for breast cancer. Bergman, L.; Beelen, M. L. R.; Gallee, M. P. W.; Hollema, H.;
Benraadt, J., and van LeeuwenF. E.. Lancet. 356(9233):881-887, 2000
Sep 9. IN PROCESS
Phase
II study of paclitaxel in patients with metastatic breast carcinoma
refractory to standard chemotherapy Rivera,
E.; Holmes, F. A.; Frye, D.; Valero, V.; Theriault, R. L.; Booser,
D.; Walters, R.; Buzdar, A. U.; Dhingra, K.; Fraschini, G., and
Hortobagyi, G. N.. Cancer. 89(11):2195-2201, 2000 Dec 1. IN PROCESS
State-of-the-art
chemotherapy for advanced breast cancer [Review]. Piccart,
M. J. and Awada, A. Seminars in Oncology. 27(5 Suppl 9):3-12, 2000
Oct. IN PROCESS Re:
Randomized trial of high-dose chemotherapy and blood cell autografts
for high-risk primary breast carcinoma Pedrazzoli,
P.; Bianchi, A. S.; Renga, M., and Siena, S. (Reprint available
from: Pedrazzoli P Osped Niguarda Ca Granda, Div Oncol Med Falck,
Dipartimento Oncol Ematol Piazza Osped Maggiore 3 I-20162 Milan
Italy). Journal of the National Cancer Institute. 92(15):1271-1272,
2000 Aug 2. NO Abstract
High-dose
chemo for breast cancer: Does it still have a chance? McNeil,
C. Journal of the National Cancer Institute. 92(12):961-962, 2000
Jun 21. No abstract Phase
I clinical trial of weekly combined paclitaxel plus docetaxel in
patients with solid tumors. Lokich,
J. Cancer. 89(11):2309-2314, 2000 Dec 1. In process
Doxorubicin
and paclitaxel in advanced breast carcinoma - Importance of prior
adjuvant anthracycline therapy. Lluch, A.; Ojeda, B.; Colomer, R.; Barnadas, A.; Massuti, B.;
Casado, A.; Angeles, C., and Maroto, P. Cancer. 89(11):2169-2175,
2000 Dec 1. In process
High-dose
chemotherapy plus autologous bone marrow transplantation for metastatic
breast cancer Lippman, M. E. (Reprint available from: Lippman ME Georgetown
Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr Washington, DC 20007
USA). New England Journal of Medicine. 342(15):1119-1120, 2000 Apr
13. No abstract
Treatment
of advanced, refractory breast cancer with alternating docetaxel
and epirubicin/cyclophosphamide plus human granulocyte colony-stimulating
factor. Kwasny,
W.; Kornek, G.; Haider, K.; Valencak, J.; Ulrich-Pur, H.; Penz,
M.; Lang, F.; Depisch, D., and Scheithauer, W.. Breast Cancer Research
& Treatment. 63(3):235-241, 2000 Oct. In process
Dose-dense
chemotherapy for breast cancer: the story so far. Hudis, C. (Reprint available from: Hudis C Mem Sloan Kettering
Canc Ctr, Breast Canc Med Serv 1275 York Ave New York, NY 10021
USA).. British Journal of Cancer. 82(12):1897-1899, 2000 Jun.
No abstract
Vinorelbine
- a clinical review [Review]. Gregory, R. K. and Smith, I. E. (Reprint available from: Smith
IE Royal Marsden NHS Trust, Dept Med Fulham Rd London SW3 6JJ England).
British Journal of Cancer. 82(12):1907-1913, 2000 Jun. No abstract
Scientific
misconduct in a breast-cancer chemotherapy trial: response of University
of the Witwatersrand. Cleaton-Jones, P. (Reprint available from: Cleaton-Jones P Univ
Witwatersrand, Comm Res Human Subjects Med Private Bag 3 ZA-2050
Wits South Africa). Lancet. 355(9208):1011-1012, 2000 Mar 18. No
abstract
Apoptosis
and proliferation as predictors of chemotherapy response in patients
with breast carcinoma. Chang, J.; Ormerod, M.; Powles, T. J.; Allred, D. C.; Ashley,
S. E., and Dowsett, M.. Cancer. 89(11):2145-2152, 2000 Dec 1. In
process
